Recent progress in liver X receptor-selective modulators

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Liver X receptors (LXRs), LXRalpha and LXRbeta, are key regulators of cholesterol metabolism and HDL formation, offering atheroprotective effects.
• However, LXRs also influence lipogenesis and can cause hypertriglyceridemia, posing challenges for drug development.
• Designing effective LXR modulators without adverse effects remains a significant hurdle in pharmaceutical research.

Purpose of the Study:

• To review current medicinal chemistry strategies for developing novel liver X receptor (LXR) modulators.
• To explore approaches for enhancing therapeutic utility and safety profiles of LXR-targeting drugs.
• To summarize the clinical development status of promising LXR modulator compounds.

Main Methods:

• Analysis of X-ray structures of LXR protein/small-molecule complexes to understand ligand-binding pocket characteristics.
• Review of medicinal chemistry literature focusing on the design of LXR modulators.
• Summarization of data from compounds that have advanced into clinical trials.

Main Results:

• LXR ligand-binding pockets are large and flexible, enabling the design of diverse ligands with varied selectivity.
• Medicinal chemistry efforts focus on balancing LXR's beneficial cholesterol efflux effects with its lipogenic impacts.
• Several LXR modulators have progressed into clinical development, indicating therapeutic potential.

Conclusions:

• Novel medicinal chemistry strategies are yielding LXR modulators with improved therapeutic potential and safety.
• Continued research into LXR modulation is vital for addressing metabolic and cardiovascular diseases.
• Understanding LXR structure-activity relationships is key to optimizing drug design for atherosclerosis treatment.